Wells Fargo & Company Durect Corp Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.43 - $5.9 $563 - $7,729	-1,310 Reduced 3.84%	32,814 $19,000
Q2 2022 Aug 12, 2022	SELL	$0.38 - $0.64 $14,323 - $24,124	-37,694 Reduced 52.49%	34,124 $16,000
Q1 2022 May 16, 2022	SELL	$0.55 - $0.98 $39,464 - $70,317	-71,753 Reduced 49.98%	71,818 $49,000
Q4 2021 Feb 14, 2022	BUY	$0.9 - $1.31 $45,109 - $65,659	50,122 Added 53.64%	143,571 $141,000
Q3 2021 Nov 15, 2021	SELL	$1.21 - $1.61 $482,543 - $642,061	-398,796 Reduced 81.02%	93,449 $119,000
Q2 2021 Aug 16, 2021	BUY	$1.6 - $2.02 $675,180 - $852,415	421,988 Added 600.63%	492,245 $802,000
Q1 2021 May 13, 2021	SELL	$1.86 - $2.87 $540,865 - $834,561	-290,788 Reduced 80.54%	70,257 $139,000
Q4 2020 Feb 09, 2021	SELL	$1.65 - $2.43 $13,825 - $20,360	-8,379 Reduced 2.27%	361,045 $747,000
Q3 2020 Nov 05, 2020	SELL	$1.6 - $2.35 $60,236 - $88,472	-37,648 Reduced 9.25%	369,424 $632,000
Q2 2020 Aug 13, 2020	BUY	$1.33 - $2.76 $162,662 - $337,556	122,303 Added 42.95%	407,072 $945,000
Q1 2020 May 14, 2020	BUY	$0.97 - $2.85 $276,225 - $811,591	284,769 New	284,769 $441,000

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $223M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.